



CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date below:

Aug. 14, 2006

Date

Charles P. Landrum

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
McBride *et al.*

Serial No.: 10/701,038

Filed: November 4, 2003

For: P153 AND P156 ANTIGENS FOR THE  
IMMUNODIAGNOSIS OF CANINE AND  
HUMAN EHRLICHIOSES AND USES  
THEREOF

Group Art Unit: 1645

Examiner: Zeman, R.

Atty. Dkt. No.: CLFR:235US

**APPEAL BRIEF**

**MS Appeal Brief - Patents**  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

## TABLE OF CONTENTS

I.	REAL PARTY IN INTEREST .....	5
II.	RELATED APPEALS AND INTERFERENCES.....	5
III.	STATUS OF THE CLAIMS .....	5
IV.	STATUS OF AMENDMENTS .....	5
V.	SUMMARY OF CLAIMED SUBJECT MATTER .....	6
VI.	GROUND OF REJECTION TO BE REVIEWED ON APPEAL .....	8
VII.	ARGUMENT .....	8
A.	Rejections under 35 U.S.C. §112.....	8
1.	Claims 6, 15, and 27-34 Satisfy the Written Description Requirement of 35 U.S.C. §112, first paragraph .....	8
2.	Claims 6, 15, and 27-34 are Definite and Satisfy the Requirements of 35 U.S.C. §112, second paragraph .....	12
B.	Objections under 37 C.F.R. §1.175.....	13
1.	Claim 30 Further Limits the Subject Matter of Claim 6.....	13
2.	Claims 31, 32, 33, and 34 are Distinct from Claims 15, 27, 28, and 29.....	14
C.	Grouping of Claims.....	14
D.	Conclusion .....	14
VIII.	CLAIMS APPENDIX.....	16
IX.	EVIDENCE APPENDIX.....	21
X.	RELATED PROCEEDINGS APPENDIX.....	29



**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
McBride *et al.*

Serial No.: 10/701,038

Filed: March 31, 2000

For: P153 AND P156 ANTIGENS FOR THE  
IMMUNODIAGNOSIS OF CANINE AND  
HUMAN EHRLICHIOSES AND USES  
THEREOF

Group Art Unit: 1645

Examiner: Zeman, R.

Atty. Dkt. No.: D6481/CLFR:235US

**APPEAL BRIEF**

**MS Appeal Brief - Patents**  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

08/16/2006 CNEGA1 00000014 10701038  
02 FC:2402 250.00 OP

Sir:

Appellants hereby submit this Appeal Brief to the Board of Patent Appeals and Interferences in response to the Office Action dated January 9, 2006. The Notice of Appeal was received by the Patent Office on May 12, 2006, as indicated by a stamped return postcard. Appellants request a one month extension of the July 12, 2006 deadline to file an Appeal Brief up to and including August 14, 2006, being that August 12, 2006 falls on a Saturday. The one-month extension fee of \$60.00 is enclosed.

The fee for filing this Appeal Brief is \$250.00 and is included herewith.

It is believed that no additional fees are due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/CLFR:235US.

Please date stamp and return the attached postcard as evidence of receipt.

## **I. REAL PARTY IN INTEREST**

The real party in interest is the assignee, Research Development Foundation, Carson City, Nevada.

## **II. RELATED APPEALS AND INTERFERENCES**

There are no related appeals or interferences.

## **III. STATUS OF THE CLAIMS**

Claims 1-26 were originally filed. In the Response filed January 18, 2005 to the Restriction Requirement dated December 15, 2004 Applicants elected Group II, Claims 6 and 15, and elected to pursue SEQ ID NO: 2, withdrawing claims 1-5, 7-14, and 16-26 from consideration. In the Response filed on September 19, 2005 to the Office action dated April 25, 2005, which was supplemented with the Response of October 17, 2005 to Notice of Non-Compliant Amendment dated September 30, 2005, claim 6 was amended and new claims 27-34 were added. The Office action dated January 9, 2006 maintained the rejection of claims 6, 15 and 27-34 as lacking written description. Thus, claims 6, 15 and 27-34 are currently pending, stand rejected, and are appealed. (see VIII. Claims Appendix).

## **IV. STATUS OF AMENDMENTS**

The final Office Action mailed January 9, 2006 acknowledges the amendments included in the Response to Notice of Non-Compliant Amendment of October 17, 2005 and in the Response to final Office Action of September 19, 2005. The Response of September 19, 2005 included amendment of claim 6 and the addition of claims 27-34. Applicants' Response on

March 9, 2006 to final Office Action mailed January 9, 2006 contained claim amendments addressing all issues outstanding in the final Office Action mailed January 9, 2006. The Advisory Action mailed March 31, 2006, denied entry of the March 9, 2006 amendments filed with the Response to Final Office action filed March 9, 2006.

## **V. SUMMARY OF CLAIMED SUBJECT MATTER**

The principal claim, claim 6, is directed to an isolated and purified polypeptide of *Ehrlichia canis* immunoreactive surface protein p153 encoded for by DNA selected from the group consisting of (a) isolated DNA which encodes a p153 protein having the amino acid sequence shown in SEQ ID NO: 2; (b) isolated DNA differing from the isolated DNA of (a) in codon sequence due to the degeneracy of the genetic code; (c) isolated DNA sequence comprising nucleotides 1080 to 1990 of *Ehrlichia canis* immunoreactive surface protein p153 gene; (d) isolated DNA sequence comprising nucleotides 1950 to 2950 of *Ehrlichia canis* immunoreactive surface protein p153 gene; and (e) isolated DNA sequence comprising nucleotides 2940 to 4220 of *Ehrlichia canis* immunoreactive surface protein p153 gene. Support for this embodiment of the invention is found, at least on page 10, lines 1-10 and page 15, lines 12-18 of the specification.

Dependent claim 15 is directed to a composition comprising an isolated and purified polypeptide of *Ehrlichia canis* immunoreactive surface protein p153 as defined in claim 6. Support for this embodiment of the invention is found, at least on page 16, lines 5-7 of the specification.

Dependent claim 27 is directed to a polypeptide described in claim 6 that is immobilized on a surface. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

Dependent claim 28 is directed to a polypeptide of claim 27 wherein the surface is a membrane. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

Dependent claim 29 is directed to a polypeptide of claim 27 wherein the surface is a microtiter plate. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

Dependent claim 30 is directed to a polypeptide of claim 6 wherein the polypeptide is an *Ehrlichia canis* immunoreactive surface protein p153 polypeptide. Support for this embodiment of the invention is found, at least on page 12 to page 14 of the specification.

Dependent claim 31 is directed to a composition comprising the peptide of claim 30. Support for this embodiment of the invention is found, at least on page 16, lines 5-7 of the specification.

Dependent claim 32 is directed to the polypeptide of claim 30 immobilized on a surface. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

Dependent claim 33 is directed to the polypeptide of claim 32 wherein the surface is a membrane. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

Dependent claim 34 is directed to the polypeptide of claim 32 wherein the surface is a microtiter plate. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

## **VI. GROUNDS OF REJECTION TO BE REVIEWED ON APPEAL**

The issues addressed in this Appeal include:

(a) Whether the written description for the sequence of an *Ehrlichia canis* immunoreactive surface protein p153 gene is sufficient under 35 U.S.C. §112, first paragraph;

(b) Whether claims 6, 15, and 27-34 are definite relative to the sequence for *Ehrlichia canis* p153 gene;

(c) Whether the subject matter of claim 30 directed to a full length p153 polypeptide, further limits claim 6 directed to segments of p153; and

(d) Whether sufficient antecedent basis is present for the term “surface” in claims 33 and 34.

## **VII. ARGUMENT**

### **A. Rejections under 35 U.S.C. §112**

#### **1. Claims 6, 15, and 27-34 Satisfy the Written Description Requirement of 35 U.S.C. §112, first paragraph**

Claims 6, 15, and 27-34 are rejected as failing to comply with the written description requirement because the claims allegedly contain subject matter not described in the specification in such way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. The



Action alleges that no baseline sequence is provided for the *E. Canis* immunoreactive surface protein p153 gene and none of the claimed proteins meet the written description requirement. The Action cites *Fiers v. Revel*, 984 F.2d 1164, 25 USPQ2d 1601, and *Amgen, Inc. v Chugai Pharmaceutical*, 927 F.2d 1200, 18 USPQ2d 1016, in support of the rejection. Applicants disagree.

Applicants have addressed the Examiner's concerns in their response to final Office Action by submitting amended claims containing reference to GenBank accession number AF252298. However, the Examiner denied entry of these claims. Nonetheless, the presently pending claims satisfy the written description requirement.

First, It is Applicants' position that the Examiner has failed to make out a prima facie case of lack of written description. As stated in the MPEP 2163(II)(A):

The examiner has the initial burden, after a thorough reading and evaluation of the content of the application, of presenting evidence or reasons why a person skilled in the art would not recognize that the written description of the invention provides support for the claims. There is a strong presumption that an adequate written description of the claimed invention is present in the specification as filed, *Wertheim*, 541 F.2d at 262, 191 USPQ at 96 [] The inquiry into whether the description requirement is met is a question of fact that must be determined on a case-by-case basis....

The MPEP also provides that an Examiner should review the entire application to understand how applicant provides support for the claimed invention. MPEP 2163(II)(A)(2) states:

Prior to determining whether the disclosure satisfies the written description requirement for the claimed subject matter, the examiner should review the claims and the entire specification, including the specific embodiments, figures, and sequence listings, to understand how applicant provides support for the various features of the claimed invention....

The present specification clearly sets forth the sequences of *Ehrlichia canis* immunoreactive surface protein p153 polypeptide and gene as provided in GenBank accession number AF252298. The Examiner's statement that "no baseline sequence is provided for [] the *Ehrlichia canis* immunoreactive surface protein p153 gene," does not establish a prima facie lack of written description, particularly in light of GenBank accession number AF252298. None of the reasons set forth in the final Office Action establish any fact that would shift the burden of establishing adequate written description to the Applicants. The Examiner has failed to provide evidence or reason why the claims read in light of the specification lack written description.

Second, Applicants provide written description for an *Ehrlichia canis* immunoreactive surface protein p153 polypeptide and gene in the specification as GenBank accession number AF252298. The specification on Page 14, line 9 to line 14 discloses the revised sequence for the *E. canis* p153 gene and polypeptide as GenBank accession number AY156950. However, the AF252298 record was updated to include the revised sequence instead of establishing the new accession number. The current AF252298 record (Exhibit 1) states that the revised sequence (a) was submitted on September 30, 2002 and (b) replaced the earlier version of accession number AF252298 (gi:12658962; Exhibit 2). Exhibit 1 is a copy of the current GenBank entry for accession number AF252298 and Exhibit 2 is a copy of GenBank entry prior to replacement with the full length p153 sequence, each of which were made of record in Applicants' Response dated September 19, 2005. Thus, GenBank accession number AF252298 provides a baseline sequence for amino acid and nucleic acid sequences of the *E. canis* immunoreactive surface protein p153 protein and gene, respectively. One of skill in the art, based on disclosure of the nucleic acid and amino acid sequence of the *E. canis* immunoreactive surface protein p153, *i.e.*, GenBank accession number AF252298, had access to the sequences of the *E. canis* immunoreactive

surface protein p153 and would have reasonably concluded that Applicants possessed the subject matter claimed as of the priority date of the present application, November 4, 2002.

In addition, the present invention is distinct from the facts underlying the *Fiers v. Revel* and *Amgen v. Chugai* cases, which were cited in support of the rejection. In these cases the conception date of a nucleic acid sequence was the date the actual DNA sequence was known and the holdings are that the description of methods for isolating a fragment of DNA and methods for isolating a corresponding mRNA is insufficient description of a nucleic acid sequence or an amino acid sequence encoded by the nucleic acid. In contrast, in the present case the DNA sequence was known and submitted to GenBank prior to the priority date of the present application. The present application does not rely on methods of isolation for identifying or describing the nucleic acid or polypeptide sequences, it discloses the sequences in the application by reference to the GenBank accession number. Therefore, the present application provides more than the mere description of the methods for isolating a DNA sequence. Thus, the holdings in *Fiers v. Revel* and *Amgen v. Chugai* are not relevant to the present application. Applicants were in possession of the invention and the GenBank accession number describes the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention.

Applicants note that none of the rejections speak to the insufficiency of GenBank accession number AF252298 and no notification of informalities regarding the sequence listing was conveyed to the Applicants during prosecution.

**2. Claims 6, 15, and 27-34 are Definite and Satisfy the Requirements of 35 U.S.C. §112, second paragraph**

Claims 6, 15, and 27-34 are rejected under 35 U.S.C. §112, second paragraph as being indefinite for failing to particularly point out and distinctly claim the subject matter Applicants regard as their invention. The claims are allegedly vague and indefinite for the following reasons: (a) claim 6 for not referencing a baseline sequence, and (b) claim 33 and 34 for lacking antecedent basis for “surface.”

**a) Claim 6, 15, 27-34 are Definite**

The Examiner alleges that no baseline sequence is provided for the claimed gene. Applicants addressed this issue by providing in the amendment after final Office Action reference to GenBank accession number AF252298. The amendment was not entered by the Examiner. Nonetheless, as discussed above and incorporated here by reference, one of skill in the art reading the claims in light of the specification would have readily recognized the baseline sequence of the *E. canis* immunoreactive surface protein p153 is GenBank accession number AF252298. The pending claims satisfy 35 U.S.C. §112, second paragraph.

**b) Claims 33 and 34**

The Examiner indicates that claims 33 and 34 lack antecedent basis for the term “surface.” Again, Applicants addressed this rejection in amendments not entered by the Examiner. However, this insufficiency is easily addressed by clarification of claim dependency and Applicants can address upon remand to the Examiner.

**B. Objections under 37 C.F.R. §1.175**

**1. Claim 30 Further Limits the Subject Matter of Claim 6**

Claim 30 is objected to as failing to further limit the subject matter of a previous claim. Applicants respectfully disagree.

Claim 30 does further limit the subject matter of claim 6. Claim 6 is directed to segments of the *E. canis* p153 protein and reads in part "...isolated DNA which encodes a p153 protein having the amino acid sequence shown in SEQ ID NO: 2." SEQ ID NO:2 represents a segment of the P153 protein. Claim 30 is directed to the full length *E. canis* protein and reads "The isolated and purified polypeptide of claim 6, wherein the polypeptide is an *Ehrlichia canis* immunoreactive surface protein p153 polypeptide." The full length *E. canis* p153 protein is described in the specification on page 14 that reads:

Anti-p43 antibody reacted with a native protein of approximately 200 kD in *E. canis* whole cell lysates. Furthermore, this 200 kD protein was also recognized by sera from an *E. canis* infected dog (Figure 5). A partial gene sequence previously identified as p43 (N-terminal portion of the p153 ) assigned GenBank accession number AF252298. The amended sequencing encoding p153 was assigned the GenBank accession number AY156950.

GenBank accession number AF252298 was amended to encompass the sequence of GenBank accession number AY15690, see above for a more detailed discussion. GenBank accession AF252298 describes the full length *E. canis* p153 polypeptide. The polypeptide segments of claim 6, in particular the segment having the amino acid sequence of SEQ ID NO:2, are not equivalent to the *Ehrlichia canis* immunoreactive surface protein p153 polypeptide of claim 30. Thus, claim 30 is distinct from and further limits the claim 6 to the full length polypeptide sequence.

**2. Claims 31, 32, 33, and 34 are Distinct from Claims 15, 27, 28, and 29**

Claims 31, 32, 33 and 34 are objected to as being substantial duplicates of claims 15, 27, 28, and 29. This objection is related to the previously argued objection related to the alleged failure to further limit the subject matter of a previous claim. The arguments set forth above relating to the objection of claim 30 are incorporated here by reference. Since claim 30 is distinct from claim 6, claims 31, 32, 33, and 34, which depend from claim 30, are distinct from claims 15, 27, 28, and 29, which depend from claim 6.

**C. Grouping of Claims**


The evidence of record overwhelmingly indicates that the present invention satisfied the requirements under 35 U.S.C. §112. In particular, that GenBank accession AF252298 describes the amino acid and nucleic acid sequence of the *E. Canis* immunoreactive surface protein p153 and provides a basis for nucleic acid and amino acid sequences presently claimed. The claims stand or fall together.

**D. Conclusion**

For the above-argued reasons, Appellants respectfully request that the rejection of claims 6, 15, and 27-34 be reversed. Appellants have provided arguments that overcome the pending rejections. Appellants respectfully submit that the Examiner's conclusion that the claims should be rejected is unwarranted. It is therefore again requested that the Board overturn the Examiner's rejection.

Please date stamp and return the enclosed postcard to evidence receipt of this document.

Respectfully submitted,



Charles P. Landrum  
Reg. No. 46,855  
Agent for Appellants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201  
(512) 536-4598 (facsimile)

Date: August 14, 2006

## VIII. CLAIMS APPENDIX

1. (Withdrawn) DNA encoding an *Ehrlichia canis* immunoreactive surface protein p153, said DNA is selected from the group consisting of:
  - (a) isolated DNA which encodes a p153 protein having the amino acid sequence of SEQ ID NO: 2; and
  - (b) isolated DNA encoding said protein, wherein the sequence of said DNA differs from the isolated DNA of (a) in codon sequence due to the degeneracy of the genetic code.
2. (Withdrawn) A vector comprising the DNA of claim 1 and regulatory elements necessary for expression of the DNA in a cell.
3. (Withdrawn) The vector of claim 2, wherein said DNA encodes a p153 protein having the amino acid sequence shown in SEQ ID NO: 2.
4. (Withdrawn) A host cell transfected with the vector of claim 2, said vector encodes a p153 protein having the amino acid sequence shown in SEQ ID NO: 2.
5. (Withdrawn) The host cell of claim 4, wherein said cell is selected from group consisting of bacterial cells, mammalian cells, plant cells and insect cells.



6. (Previously presented) An isolated and purified polypeptide of *Ehrlichia canis* immunoreactive surface protein p153 encoded for by DNA selected from the group consisting of:

(a) isolated DNA which encodes a p153 protein having the amino acid sequence shown in SEQ ID NO: 2;

(b) isolated DNA differing from the isolated DNA of (a) in codon sequence due to the degeneracy of the genetic code;

(c) isolated DNA sequence comprising nucleotides 1080 to 1990 of *Ehrlichia canis* immunoreactive surface protein p153 gene;

(d) isolated DNA sequence comprising nucleotides 1950 to 2950 of *Ehrlichia canis* immunoreactive surface protein p153 gene; and

(e) isolated DNA sequence comprising nucleotides 2940 to 4220 of *Ehrlichia canis* immunoreactive surface protein p153 gene.

7. (Withdrawn) DNA encoding an *Ehrlichia chaffeensis* immunoreactive surface protein p156, said DNA is selected from the group consisting of:

(a) isolated DNA which encodes a p156 protein having the amino acid sequence of SEQ ID NO: 1; and

(b) isolated DNA encoding said protein, wherein the sequence of said DNA differs from the isolated DNA of (a) in codon sequence due to the degeneracy of the genetic code.

8. (Withdrawn) A vector comprising the DNA of claim 7 and regulatory elements necessary for expression of the DNA in a cell.

9. (Withdrawn) The vector of claim 8, wherein said DNA encodes a p156 protein having the amino acid sequence shown in SEQ ID NO: 1.

10. (Withdrawn) A host cell transfected with the vector of claim 8, said vector encodes a p156 protein having the amino acid sequence shown in SEQ ID NO: 1.
11. (Withdrawn) The host cell of claim 10, wherein said cell is selected from group consisting of bacterial cells, mammalian cells, plant cells and insect cells.
12. (Withdrawn) Isolated and purified *Ehrlichia chaffeensis* immunoreactive surface protein p156 encoded for by DNA selected from the group consisting of:
  - (a) isolated DNA which encodes a p156 protein having the amino acid sequence shown in SEQ ID NO: 1; and
  - (b) isolated DNA differing from the isolated DNA of (a) in codon sequence due to the degeneracy of the genetic code.
13. (Withdrawn) An antibody directed against the p153 protein of claim 6.
14. (Withdrawn) An antibody directed against the p156 protein of claim 12.
15. (Previously presented) A composition comprising a p153 polypeptide of claim 6.
16. (Withdrawn) A vaccine against canine ehrlichiosis comprising the p156 protein of claim 12.
17. (Withdrawn) A method of determining whether a dog is infected with an *Ehrlichia* species, comprising the step of: determining whether serum from said dog reacts with *E. canis* p153 protein or *E. chaffeensis* p 156 protein, wherein reaction with the p153 protein or the p156 protein indicates said dog is infected with *Ehrlichia canis* and *Ehrlichia chaffeensis*, respectively.
18. (Withdrawn) The method of claim 17, wherein said protein is a recombinant protein.
19. (Withdrawn) The method of claim 17, wherein western blot analysis is used to determine whether the serum of said dog reacts with said protein.
20. (Withdrawn) The method of claim 17, further comprising the step of determining whether the serum from said dog reacts with *E. canis* p28 protein, wherein

immunoreactivity to both the p153 and p28 proteins indicates said dog is infected with *Ehrlichia canis*.

21. (Withdrawn) A serodiagnostic kit for determining whether a dog is infected with an *Ehrlichia* species, said kit comprising: a) one or more immobilized *Ehrlichia* antigens selected from the group consisting of p153, p43, p156 and p28; b) appropriate dilution buffers for dog serum; c) an anti-dog serum second antibody linked to a reporter molecule; and, d) appropriate reagents for detection of said reporter molecule.
22. (Withdrawn) The kit of claim 21 wherein said *Ehrlichia* antigens are immobilized on a membrane or a microtiter plate.
23. (Withdrawn) The kit of claim 21, wherein said reporter molecule is selected from the group consisting of luciferase, horseradish peroxidase,  $\beta$ -galactosidase, and fluorescent labels.
24. (Withdrawn) A method of determining whether a dog has been infected with an *Ehrlichia* species, comprising the steps of: extracting DNA from the blood of said dog; and performing PCR amplification on said DNA with oligonucleotide primers specific for the *E. canis* p153 gene or the *E. chaffeensis* p156 gene; separating the resulting PCR product by size, wherein positive detection of an appropriately sized amplification product indicates infection with *E. canis* or *E. chaffeensis*.
25. (Withdrawn) The method of claim 24, wherein said PCR product is detected by gel electrophoresis.
26. (Withdrawn) A kit for determining whether a dog is infected with an *Ehrlichia* species, said kit comprising: a) reagents for DNA extraction from blood; b) p153-specific or p156-specific oligonucleotides; reagents for DNA extraction from blood; and, c) reagents for PCR amplification.
27. (Previously Presented) The isolated and purified polypeptide of claim 6, wherein the protein is immobilized on a surface.



28. (Previously Presented) The isolated and purified polypeptide of claim 27, wherein the surface is a membrane.
29. (Previously Presented) The isolated and purified polypeptide of claim 27, wherein the surface is a microtiter plate.
30. (Previously Presented) The isolated and purified polypeptide of claim 6, wherein the polypeptide is an *Ehrlichia canis* immunoreactive surface protein p153 polypeptide.
31. (Previously Presented) A composition comprising a p153 polypeptide of claim 30.
32. (Previously Presented) The isolated and purified polypeptide of claim 30, wherein the protein is immobilized on a surface.
33. (Previously Presented) The isolated and purified polypeptide of claim 30, wherein the surface is a membrane.
34. (Previously Presented) The isolated and purified polypeptide of claim 30, wherein the surface is a microtiter plate.

## **IX. EVIDENCE APPENDIX**

Exhibit 1 – Copy of GenBank accession number AF252298 (gi:37528969), made of record in Applicants Response dated September 19, 2005 to the non-final Office Action mailed April 25, 2005 as Exhibit 2.

Exhibit 2 – Copy of GenBank accession number AF252298 (gi:12658962), made of record in Applicants Response dated September 19, 2005 to the non-final Office Action mailed April 25, 2005 as Exhibit 1.

# **EXHIBIT 1**

[PubMed](#)
[Nucleotide](#)
[Protein](#)
[Genome](#)
[Structure](#)
[PMC](#)
[Taxonomy](#)
[OMIM](#)
[Books](#)

Search  for

[Limits](#)
[Preview/Index](#)
[History](#)
[Clipboard](#)
[Details](#)

Display  Show  Send to

Range: from  to 
☐ Reverse complemented strand
 Features: ☐ SNP ☒ CDD ☐

☐ 1: [AF252298](#). Reports *Ehrlichia canis* 2...[gi:37528969]

[Links](#)

[Comment](#) [Features](#) [Sequence](#)

**LOCUS** AF252298 4266 bp DNA linear BCT 06-OCT-2003  
**DEFINITION** *Ehrlichia canis* 200 kDa immunoreactive glycoprotein gene, complete cds.  
**ACCESSION** AF252298  
**VERSION** AF252298.2 GI:37528969  
**KEYWORDS** .  
**SOURCE** *Ehrlichia canis*  
**ORGANISM** *Ehrlichia canis*  
 Bacteria; Proteobacteria; Alphaproteobacteria; Rickettsiales; Anaplasmataceae; Ehrlichia.  
**REFERENCE** 1 (bases 1 to 4266)  
**AUTHORS** McBride, J.W., Corstvet, R.E., Breitschwerdt, E.B. and Walker, D.H.  
**TITLE** Immunodiagnosis of *Ehrlichia canis* infection with recombinant proteins  
**JOURNAL** J. Clin. Microbiol. 39 (1), 315-322 (2001)  
**PUBMED** 11136790  
**REFERENCE** 2 (bases 1 to 4266)  
**AUTHORS** McBride, J.W., Comer, J.E. and Walker, D.H.  
**TITLE** Novel Immunoreactive Glycoprotein Orthologs of *Ehrlichia* spp  
**JOURNAL** Ann. N. Y. Acad. Sci. (2003) In press  
**REFERENCE** 3 (bases 1 to 4266)  
**AUTHORS** McBride, J.W. and Walker, D.H.  
**TITLE** Direct Submission  
**JOURNAL** Submitted (04-APR-2000) Pathology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA  
**REFERENCE** 4 (bases 1 to 4266)  
**AUTHORS** McBride, J.W. and Walker, D.H.  
**TITLE** Direct Submission  
**JOURNAL** Submitted (30-SEP-2002) Pathology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA  
**COMMENT** On Oct 6, 2003 this sequence version replaced gi:12658962.  
**FEATURES**  
**source** 1..4266  
 /organism="Ehrlichia canis"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:944"  
**CDS** 1..4266  
 /note="gp200"  
 /codon\_start=1  
 /transl\_table=11  
 /product="200 kDa immunoreactive glycoprotein"  
 /protein\_id="AAK01145.2"  
 /db\_xref="GI:37528970"

```

/translation="MSDPKQGDPEQNQTNPSGDIQDQSQDQDQEQDQDQDQAVGGAVGN
SPIERERVAAPESDLYTVIIPKGRKTAAPILERKSPTPEPKVEDDEDLPPTLPPTF
SGEGYDDVGVSMPTVSRGIYQPPIVQDSNLYSSIGGVPQEAQYDAAARAGGPRKFLYG
PYTFSNGQEIMDFEFDTPWPDVRNAV LGNKEIKEEWLTTSGPVRDIADRIVASKGDL
EDQVEEILDII FMNESEIAEGISNPLHADVDNPNVKGAKNVM TLMHLVYACDVPRI
KALGEVENDEGDLGANAYNVLDSEGNLPLHHA AKNCTGDKL KLCMEKTKTDFIDTANF
ANQSP LHIITQKPD C S V L D I E E F T S R N L D F G L V D G D G K N P L H H A V E H L P P V I L K G V M D
HVKNSSEFQDLVNDPDYFGNTIAHYAVKNKNADLT LFNMLKASGADLNVRNVVGRAP
HVASSNGKANAVSGLVSCGIDVNSQDVNGDTP L H I A V E G G S M E T V L A V L N Q R G A D V S V
QNN DG V T P M L S A A K Y G D I G V I K A L G S A K P N I K G E D T V A K S L L M E D Y K G F T P L H F V A G G
GSRD T F R V V R K N Y E K C H D L A T I R A A L M Q D R S G G E L V N L G D F E S E N I L G S P N A K F L Q H I
Q S A N F G F S P A R R G I V S S N H N V M K D I L N F V G D S L H L P S E R G Y N A M Q V A A L F G D K E A V K M
L A K S A K P S D L N F K T S A T P T P L N L A C L R G D N E V V R G L V G Q H G I D I N Q R M G S D K N T V L H Y
A I S K G D S F L V Q K I L A H T G V D V N C E N N L G Q T P L H L A V E G G D P K I V S S L L K A G A V N R L D
D N G R S V L S S A I V P G R K E K G V L G I V N K L L D R G A D I N L D G D H N I L F D Q C L R G G Y N N V L D K
L I Q Q G V E V N R N S E I R P M V Y A A I S G N E H A I K S L A N A G G D V N E V N N P S R H S C N P L I M V
A V A D G N A G L L K T L V S E G C D V G K S G K D G N T A L H Y A V S H S D K E F G N K A I K I L I S R N S V G T
N R D I L T Q K N N A G D T P L H E A L K S G N I N S V Q N I L S A V H P R Y A K E I L T A R D K E G Y T P M H Y T
V G V N N V D V G R S I L E S M L S K G V N N L G E I V G A Q D S N F R T P L H A A I K I S D Y R A A D M I I G S L
S K T E L S K L S Q L T D I N G D T P L H L S C Q S G N V E M T Q F F L G G L D K R E L P K T L K I A N K N G D T P
L H D A I R N D D I K S A K M M I R N C N K E E L A N V L K C K D S F G N T V L H T I A D Q V I A N P E S K K O L D
G L M N L A V K R L K N Q D L K D L V N T R N S D D T V A H C A L L S D M K Y A Q K I L K S C N H D T L V R G N S
N N Q S L S E C I R D D S K Y K K G G I F S K S L F S K L K L E A R A A S A S Y E E L S S I S S G S D V S S V S T
N S T E V S A V P E A R S S G A V S F K H V Q E T G V D T S G P S D I E S L E R L S D T S L G S N D F D Q R M A D
L D Q E I A N I V S G L P E V T Q V A V S Q Q Q A A S P S S G Q A A G V Q Q K E M Q R "

```

## ORIGIN

```

1 atgtcagatc caaaacaagg tgatccagaa caaaatcaaa ctaaccctag tgggtgatatt
61 caggatcaaa gtcagcaaga tcaacaggaa caagatcagc agcagggagc agttgggtggt
121 gctggttgta atagtcctat tgaaagagag agagtagctg ctcctgagag tgaagattta
181 tatactgtga ttatacctaa gggtaaaaga actgctgctc caattttgga aagaaagtct
241 cctactcctg aaccgaaagt agaagatgat gaagatttac ctcctacatt accgccaaga
301 acattttcag gagaaggata tgatgacgtt ggagttagta tgcctactgt tggcgtggc
361 atataccaac tcccatagat tcaagatagt aatctatatt caagtattgg tggcgtacca
421 caagaagcac aatatgatgc agcagctcgg gctgggtggc caagaaagtt tttgtatggg
481 ccatatacat tcagtaatgg tcaggaaatt atggactttg aatttgatac tccttgcca
541 gatgttagga atgcagtttt aggtaataaa gagataaaag aagagtgggt aactacttct
601 gggccagtac gtgatattgc tgataggata gttgcttcta aagggtgatt gtctgaggat
661 caagtagaag aaatccttga tattatattt atgaatgaat cagaaatcgc tgaagggtatt
721 tctaatecat tacatgctga tgttgataat aatcctgtta aagggtgctaa gaatgtgatg
781 acattgatgc atctagttta tgcagtgtat gttgatccac gtatagtaaa agcttttagga
841 gaggtggaaa atgatgaagg tgatttagga gctaattgct ataattgttt agatagttag
901 ggtaatcttc ctttacatca tgctgcaaaag aattgtacag gggataagtt aaagctttgt
961 atggagaaaa caaagactga ttttattgat actgcaaatt ttgcgaatca atccccctta
1021 catattatta cacagaagcc agattgttct gtattagata ttgaagagtt tacaagccgt
1081 aatttagatt ttggacttgt agatggagat ggtaaaaatc ctttacatca tgctgttgaa
1141 catttgccac ctgttatact taagggcgta atggaccatg taaaaaatag tagtgagttt
1201 caagatttag taaatgatcc tgattatttt ggaataacta tagctcatta tgcagttaag
1261 aataaaaatg ctgatttaac attgtttaac atgctgaaag cttcaggagc tgattttaat
1321 gttaggaatg tagttggtcg agctccaata catgttgctt cttctaattg taaggctaatt
1381 gcagtttctg gacttgatc atgtggtatt gacgttaatt ctcaagatgt gaatggagat
1441 acaccacttc atattgctgt tgaaggcggg agtatggaga cggtattagc agtggttaaat
1501 cagagaggtg ctgatgttag tgtccagaat aacgatggag ttacacctat gcttagtgct
1561 gctaaatag gagatatagg tgtaataaaa gctttagggt cagctaaacc aaatatataa
1621 ggtgaagaca ctgttgctaa atcattgctg atggaggatt acaaagggtt tacacccttg
1681 ctttttgtag ctggtgggtg tagcagagat acattccgtg tcgtaagaaa aaattatgaa
1741 aaatgtcatg acttagctac tattagggca gctttaatgc aagatagaag tgggtggtgag
1801 cttgtaaatt taggggattt tgaaagtga aatatattgg gttcgccaaa tgcaaaattc
1861 ttgcagcata ttcaatcagc aaattttggt ttttctccag cgcgaagggg tatagtatcg
1921 tctaatacaca atgtaatgaa agatatctta aattttgttg gggattcgtt acacctacca
1981 agtgagcgtg ggtataatgc aatgcagggt gctgctttgt ttggtgacaa agaagcagtg

```



2041 aaaatgcttg ctaaaagtgc taagccaagt gatcttaatt ttaagacttc agcaactcct  
2101 actccggttaa atcttgcatg tcttagaggt gataatgagg tagtacgtgg gttagtaggt  
2161 caacatggta ttgacattaa ccaacgtatg ggaagtgata aaaacactgt attgcattat  
2221 gcaatcagca aaggagatag ttttcttggtg caaaagatat tagctcatatc tggagttgat  
2281 gttaattgtg agaataacct aggtcaaacg cctttacatt tagcagttga gggaggagat  
2341 cctaagatag tatcttctct tcttaaagct ggtgcagtag ttaatcgctt ggatgataat  
2401 ggtagatctg tactttcttc tgcgatagtt ccaggtagaa aagaaaaggg agtgctgggt  
2461 atagttaata aattgctgga tagaggtgca gatattaatt tagatggaga ccacaatata  
2521 ctttttgatc agtgtctaaag ggggtgatat aataatgtat tagataagtt aatacaacaa  
2581 ggggttgaag ttaatcgaaa tagtgaaata cgtccaatgg tttatgctgc aatatctggt  
2641 aatgagcatg ctatcaaatac attagctaata gctgggtggag atgttaatga agtagtaaat  
2701 aatccatcta gtaggcattc aggaaatcct ttaattatgg ttgcagtagc agatggtaat  
2761 gcagggtcttc ttaaaacatt agtttctgaa ggatgtgatg ttggtaaatc tggaaaagat  
2821 ggtaatacag cgttacatta tgctgttagt cattcagata aagagtttgg taataaagct  
2881 ataaagatat taatttcacg taatagtgtt gggactaata gagatattct tactcaaaag  
2941 aataacgcag gtgatacacc tttacatgaa gctcttaagt caggtaatat taattctgta  
3001 cagaatatct taagtgtgtt acatccaaga tacgcaaagg agatattaac agccagagac  
3061 aaagaagggt acacaccaat gcattatact gttggagtaa ataatgttga tgttggtaga  
3121 agtattctag agtctatgct ctctaaagggt gtgaataatc ttggagagat tgttgtagca  
3181 caggatagta attttcgaac acctctgcat gctgctatta aaatatctga ttatcgtgct  
3241 gcggacatga taataggtag cttatcgaaa acagaattgt caaagttatc gcaattaaca  
3301 gatattaacg gggatacacc actacatctt tcttgctcagt ctggtaatgt cgagatgaca  
3361 caattctttc ttggagggtt ggataaacgt gaattaccta agacattaaa gatagcaaat  
3421 aaaaatggag atactccttt acatgatgct ataagaaatg atgatattaa atctgcaaaa  
3481 atgatgatta ggaattgtaa caaagaagaa cttgctaattg tattaaaatg taaagatagt  
3541 tttggttaata cagtattgca tactattgct gaccaagtta ttgcgaatcc agaatacaag  
3601 aaagaccttg atgggttgat gaatttagca gtgaaaaggc taaagaatca agatctgaaa  
3661 gatctagtta atacgcgaaa taactctgac gatactgttg cacattgtgc tcttttatcg  
3721 gatatgaaat atgctcaaaa gatacttaaa tcatgtaacc atgatacatt agtgagagga  
3781 aatagtaata atcaatcttt atcagagtgt attcgtgatg atagtaaata taaaaaagggt  
3841 ggaattttta gtaagtcttt attttcaaaa ttaaagaaac ttgaggcacg agctgccagc  
3901 gctagttagt aagaattatc tagtatcagt agtggtagtg atgtttcttc tgtatcaaca  
3961 aatagcacag aagtaagtgc agtacctgaa gtggcaagaa gtagtggtgc tgtgtcgttc  
4021 aaacatgtgc aagaaacagg agttgacacg tctggtcctt ctgatataga aagtttagag  
4081 agattatctg atactagtct tgggtcaaat gattttgatc agcgaatggc agatttagat  
4141 caagaaatag caaatattgt tagtggttta ccagaagtta cccaggtagc tgtaagtcaa  
4201 caacaagcag catctcctag ttcagggtcaa gctgctggtg tgcaacaaaa agagatgcag  
4261 agataa

//

[Disclaimer](#) | [Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)

## **EXHIBIT 2**

NCBI Nucleotide

My NCBI [Sign In] [Register]

PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search Nucleotide for [Go] [Clear]

Limits Preview/Index History Clipboard Details

Display GenBank Show 5 Send to

Range: from begin to end Reverse complemented strand Features: [Refresh]

1: AF252298. Reports ...[gi:12658962] The record has been replaced by 37528969

[Comment](#) [Features](#) [Sequence](#)

LOCUS AF252298 1173 bp DNA linear BCT 05-FEB-2001  
DEFINITION Ehrlichia canis 43 kDa surface protein gene, complete cds.  
ACCESSION AF252298  
VERSION AF252298.1 GI:12658962  
KEYWORDS  
SOURCE Ehrlichia canis  
ORGANISM Ehrlichia canis  
Bacteria; Proteobacteria; Alphaproteobacteria; Rickettsiales;  
Anaplasmataceae; Ehrlichia.  
REFERENCE 1 (bases 1 to 1173)  
AUTHORS McBride, J.W., Corstvet, R.E., Breitschwerdt, E.B. and Walker, D.H.  
TITLE Immunodiagnosis of Ehrlichia canis infection with recombinant  
proteins  
JOURNAL J. Clin. Microbiol. 39 (1), 315-322 (2001)  
PUBMED 11136790  
REFERENCE 2 (bases 1 to 1173)  
AUTHORS McBride, J.W. and Walker, D.H.  
TITLE Direct Submission  
JOURNAL Submitted (04-APR-2000) Pathology, University of Texas Medical  
Branch, 301 University Blvd., Galveston, TX 77555, USA  
COMMENT [WARNING] On Oct 6, 2003 this sequence was replaced by a newer  
version gi:37528969.  
FEATURES  
source Location/Qualifiers  
1..1173  
/organism="Ehrlichia canis"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:944"  
CDS 1..1173  
/codon\_start=1  
/transl\_table=11  
/product="43 kDa surface protein"  
/protein\_id="AAK01145.1"  
/db\_xref="GI:12658963"  
/translation="MSDPKQGDPEQNQTNP SGDIQDQSQQDQEQDQQQGA VVGAVGN  
SPIERERVAAPESEDLYTVIIPKGRTAAPILERKSPTPEPKVEDDEDLPPTLPPTF  
SGEGYDDVGVSMP TVSRGIYQPPIVQDSNLYSSIGGVPOEAQYDAAARAGGPRKFLYG  
PYTFSNGQEIMDFEFTPWPDVRNAV LGNKEIKEWLTTSGPVRDIADRI VASKGDL  
EDQVEEILD IIFMNESEIAEGISNPLHADVDNNPVKGAKNVTLMHLVYACDVPRI  
KALGEVENEDEGLGANAYNVLDSEGNLPLHHA AKNCTGDKLKLCKMEKTKTDFIDTANF  
ANQSPLHIITQKPDCSVLDIEEFTSRNLDFGLVDGDGKNPLH HAVEHLPPVNLKGR"  
ORIGIN  
1 atgtcagatc caaaacaagg tgatccagaa caaaatcaaa ctaaccctag tggatgatt  
61 caggatcaaa gtcagcaaga tcaacaggaa caagatcagc agcagggagc agttgggagg

121 gctgttggtgta atagtcctat tgaaagagag agagtagctg ctcctgagag tgaagattta  
181 tatactgtga ttatacctaa gggtaaaaga actgctgctc caatttttga aagaaagtct  
241 cctactcctg aaccgaaagt agaagatgat gaagatttac ctcctacatt accgccaaga  
301 acatttttcag gagaaggata tgatgacgtt ggagtttagta tgcctactgt tagtcgtggc  
361 atataccaac ctcccatagt tcaagatagt aatctatatt caagtattgg tggcgtacca  
421 caagaagcac aatatgatgc agcagctcgg gctgggtggc caagaaagt tttgtatggg  
481 ccatatacat tcagtaatgg tcaggaaatt atggactttg aatttgatac tccttggcca  
541 gatgttagga atgcagtttt aggtaataaa gagataaaaag aagagtgggt aactacttct  
601 gggccagtac gtgatattgc tgataggata gttgcttcta aagggtgatt gtctgaggat  
661 caagtagaag aaatccttga tattatattt atgaatgaat cagaaatcgc tgaaggtatt  
721 tctaattccat tacatgctga tgttgataat aatcctgtta aagggtgctaa gaatgtgatg  
781 acattgatgc atctagttta tgcattgtgat gttgatccac gtatagtaaa agcttttagga  
841 gaggtggaaa atgatgaagg tgatttagga gctaattgctt ataattgttt agatagttag  
901 ggtaatcttc ctttacatca tgctgcaaag aattgtacag gggataagtt aaagctttgt  
961 atggagaaaa caaagactga ttttattgat actgcaaatt ttgcgaatca atccccttta  
1021 catattatta cacagaagcc agattgttct gtattagata ttgaagagtt tacaagccgt  
1081 aatttagatt ttggacttgt agatggagat ggtaaaaatc ctttacatca tgctgttgaa  
1141 catttgccac ctgttaactt aaaggggcgg taa

//

[Disclaimer](#) | [Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)

Jul 24 2006 17:22:14

**X. RELATED PROCEEDINGS APPENDIX**

NONE.